Expression of MCM7 and CDC6 in oral squamous cell carcinoma and pre-cancerous lesions

Department of Stomatology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Anticancer research (Impact Factor: 1.83). 11/2008; 28(6A):3763-9.
Source: PubMed


The present study aimed at evaluating the clinical importance of Mcm7 and Cdc6 expression in oral squamous cell carcinoma (OSCC) and precancerous lesions.
RT-PCR and immunohistochemistry analysis were performed on 47 frozen samples and 98 paraffin-embedded samples to evaluate the mRNA and protein expressions of Mcm7 and Cdc6.
RT-PCR and immunohistochemistry indicated positive expressions of Mcm7 mRNA and protein in normal oral mucosa, precancerous lesions and OSCC. Significant differences were found between all the groups. Cdc6 mRNA and protein had low expressions in normal oral mucosa but were highly expressed in precancerous lesions and OSCC. Mcm7 and Cdc6 expressions in the lymph node metastasis cases were significantly higher than those of the nonmetastatic carcinomas.
High expressions of Mcm7 and Cdc6 are correlated with the development and metastasis of OSCC and may become a molecular marker for the early diagnosis and prognosis prediction for OSCC.

Download full-text


Available from: Yong-jun Lu, Feb 16, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Minichromosome maintenance (MCM) proteins act as the origin licensing machinery that regulates initiation of DNA replication. Geminin is a licensing repressor and prevents reinitiation of DNA replication by blocking reloading of MCM proteins at replication origins. Recent studies have proposed that MCM7 and geminin may be sensitive proliferative and prognostic markers of various malignant tumors. This study aimed to analyze the expression of MCM7 and geminin to clarify pathobiological significance in human oral squamous cell carcinomas (OSCCs). We performed immunohistochemical analysis on 10 specimens of normal oral epithelia, 50 lesions with dysplasia and 113 OSCCs. Labeling indices (LIs) for MCM7, geminin and Ki-67 were evaluated, comparing with clinicopathological profiles. The mean LIs for MCM7 were 29.2% for normal epithelia, 32.2% for dysplasias, and 51.1% for OSCCs; the value was significantly higher in the last than in the former two (P < 0.01). The mean LIs for geminin were 6.8% for normal epithelia, 9.2% for dysplasias, and 21.3% for OSCCs; the value was significantly higher in the OSCCs (P < 0.01). The MCM7 LIs were correlated with the histological grade of OSCCs, in which the highest LIs were noted in the poorly differentiated type (P < 0.01). The survival rate was significantly lower in patients with a higher MCM7 LI (>49.5%) than in those with a lower LI (P < 0.05) at stage III-IV. However, the survival rate in the patients with a higher geminin LI (>19.5%) was significantly higher than in those with a lower LI (P < 0.05) at stage IV.
    Journal of Oral Pathology and Medicine 02/2010; 39(4):328-34. DOI:10.1111/j.1600-0714.2009.00861.x · 1.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cell division cycle protein 6 (CDC6) plays critical roles in DNA replication and carcinogenesis. The biological significance of the CDC6 G1321A polymorphism (V441I, rs13706) on cervical carcinogenesis is still unknown. Here, we examined the potential influence of this polymorphism on cell proliferation and the individual's susceptibility to cervical cancer. We genotyped the CDC6 G1321A polymorphism in 87 cervical cancer cases and 110 healthy female subjects. Unconditional logistic regression analysis was used to estimate the association between the genotypes and the risk of cervical cancer. The BrdU incorporation assay was applied to analyze the effect of this polymorphism on cell proliferation. Compared with the GG homozygotes, the cervical cancer risk was significantly reduced in the individuals with the heterozygous AG genotype (odds ratio [OR], 0.53; 95% confidence interval [CI], 0.28-0.98; P = 0.042) or the homozygous AA genotype (OR, 0.29; 95% CI, 0.09-0.89; P = 0.030). Further stratified analyses showed that the decreased risk of cervical cancer was more evident among younger subjects (≤44 years old) with the AG or AA genotypes (OR, 0.44; 95% CI, 0.21-0.92; P = 0.029 and OR, 0.12; 95% CI, 0.03-0.61; P = 0.010, respectively). The BrdU incorporation assay showed that 293T cells transfected with CDC6-441I (1321A) had a lower proliferation rate in comparison with those transfected with CDC6-441V (1321G), although the difference did not reach statistical significance at the 0.05 level. The CDC6 G1321A polymorphism may contribute to the risk of cervical cancer. Further studies with more subjects and in diverse ethnic populations are necessary to confirm the general validity of our findings.
    International Journal of Gynecological Cancer 07/2010; 20(5):856-61. DOI:10.1111/IGC.0b013e3181df3cab · 1.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Minichromosome complex maintenance component 7 (MCM7) is a critical component of DNA replication licensing. Amplification and overexpression of MCM7 leads to high rate of prostate cancer metastasis. Recent studies indicate that MCM7 genome encodes a putative 'super-oncogene' cluster including MCM7 oncogene and a miRNA cluster that knocks down the expression of several critical tumor-suppressor genes. In this study, we constructed a vector that constitutively expresses small interference RNA (siRNA) specific for MCM7. Introduction of this vector into prostate cancer cell lines PC3 or Du145 decreases the expression of MCM7 by 80%. The vector inhibits DNA synthesis and generates growth arrest of these cancer cells. Severe combined immunodeficient mice were xenografted PC3 or Du145 tumors, and subsequently treated with this vector through tail vein injection with polyethylenimine. The animals had dramatically smaller tumor volume, less metastasis and better survival rate in comparison with the controls. As a result, intervention of MCM7 expression using siRNA approach may hold the promise for treating androgen refractory prostate cancer.
    Cancer gene therapy 10/2010; 17(10):694-9. DOI:10.1038/cgt.2010.25 · 2.42 Impact Factor
Show more